The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Assessment of Hand Grip Strength Using Jamar Dynamometer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05939908
Recruitment Status : Recruiting
First Posted : July 11, 2023
Last Update Posted : July 11, 2023
Sponsor:
Collaborator:
National Diabetes Obesity and Cholesterol Foundation
Information provided by (Responsible Party):
Dr Anoop Misra, Diabetes Foundation, India

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Hand grip strength will be measured for all the type 2 diabetic patients. Measurement of maximal grip strength will be performed using Jamar dynamometers, which estimate the muscle strength primarily generated by the flexor muscles of the hand and the forearm. The Jamar displays grip force in both pounds and kilograms, with a maximum of 200 lb (90 kg). It has a peak-hold needle that automatically retains the highest reading until reset. The Jamar test is isometric, with no perceptible motion of the handle, regardless of the grip strength applied. The participants will be encouraged to produce their maximal grip strength. Three trials will be recorded, consisting of a 2-4-second maximal contraction, with a 30-second rest period between each trial. The average of the three readings will be taken.

Condition or disease Intervention/treatment
Type2diabetes Other: Using Jamar Dynamometer for Grip Strength.

Detailed Description:

Sarcopenia is an age related, progressive, and generalized skeletal muscle disorder involving the accelerated loss of muscle mass and function and physical performance below a defined threshold1. It is associated with increased adverse outcomes including increased risk falls, physical frailty, prolonged hospitalization, dependency, physical disability and impairment, limitation of mobility, decreased quality of life and increased mortality. Sarcopenia is known to be more prevalent in older populations, but the decline in muscle mass starts from ~40 years onwards2.

Sarcopenia not only affects the ability to lead an active lifestyle but also contributes to increased obesity, type 2 diabetes (T2DM) reduced quality of life, osteoporosis, and metabolic health1.

Hand grip strength (HGS) is considered as an important value when diagnosing sarcopenia. Lower muscle strength using HGS is mandatory to diagnose sarcopenia. EWGSOP group recommends that the mean reference cut-off value of hand grip is < 30 kg in men and < 20 kg in women.

There is evidence that strength could be an important risk factor for diabetes. Low hand-grip strength has been predictive of incident diabetes in prospective cohort studies3. Lower grip strength was associated with higher prevalence of diabetes, independent of confounding factors, across all ethnicities in both men and women. Diabetes prevalence was approximately three- to fourfold higher in South Asian participants across all levels of grip strength3 .

However, there are no studies in India assessing sarcopenia in type 2 diabetic patients.

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 5000 participants
Observational Model: Other
Time Perspective: Other
Official Title: To Assess Prevalence of Sarcopenia Using Hand Grip Strength (HGS) as a Marker in Patients With T2DM
Actual Study Start Date : July 1, 2023
Estimated Primary Completion Date : December 31, 2024
Estimated Study Completion Date : January 30, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Intervention Details:
  • Other: Using Jamar Dynamometer for Grip Strength.
    Hand grip strength as a marker by using JAMAR hand grip dynamometer in patients with T2DM.

Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Comparison of age and gender specific prevalence of sarcopenia using HGS in patients with T2DM [ Time Frame: 6 days ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
T2DM patient visiting Fortis CDOC Hospital and meeting the Inclusion Criteria will be enrolled in the study.
Criteria

Inclusion Criteria:

All patients with Type 2 diabetes of any duration coming for first time in OPD

Exclusion Criteria:

  1. Patients with hand fracture
  2. Thyroid dysfunction
  3. Any musculoskeletal condition causing difficulty in holding the dynamometer
  4. Patients with type1 diabetes (T1DM) and gestational diabetes (GDM)
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05939908


Contacts
Layout table for location contacts
Contact: Anoop Misra, MD 01149101222 anoopmisra@gmail.com
Contact: Bhavya Arora, M.Sc 01149101222 bhavyam_1010@yahoo.co.in

Locations
Layout table for location information
India
Fortis CDOC Hospital Recruiting
Delhi, India, 110048
Contact: Anoop Misra, MD    01149101222    anoopmisra@gmail.com   
Principal Investigator: Anoop Misra, MD         
Sub-Investigator: Bhavya Arora, M.Sc         
Sponsors and Collaborators
Diabetes Foundation, India
National Diabetes Obesity and Cholesterol Foundation
Investigators
Layout table for investigator information
Principal Investigator: Anoop Misra, MD Fortis CDOC Hospital
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Dr Anoop Misra, Director, Diabetes Foundation, India
ClinicalTrials.gov Identifier: NCT05939908    
Other Study ID Numbers: HGS
First Posted: July 11, 2023    Key Record Dates
Last Update Posted: July 11, 2023
Last Verified: July 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No